Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy

home / rapid-readouts / pegcetacoplan-vs-avacincaptad-pegol-in-patients-with-geographic-atrophy

In this Rapid Readout, Dr Paul Hahn shares his presentation from the 2023 ASRS annual meeting. This study compares the efficacy of the two FDA-approved treatments for geographic atrophy based on an anchored matching-adjusted indirect comparison of the phase 3 trials.

© 2024 MJH Life Sciences

All rights reserved.